Metaplastic breast carcinoma with osseous remnant post standard treatment of invasive ductal carcinoma: case report and review of literature
Keywords:
metaplastic breast carcinoma, osseous differentiation, treatment, remnantAbstract
Metaplastic breast carcinoma (MBC) is a rare subgroup of breast cancers that behave more aggressive in comparison with other breast cancer subtypes. Among them, the osseous variant is the rarest variant. Histologically, it consists of a metaplastic component beside main adenocarcinoma component. Consequently, this extra metaplastic part of MBC can justify more aggressive and chemoresistant behavior of metaplastic breast carcinoma. We present a case of a middle-aged female with metaplastic breast cancer that following standard chemotherapy of invasive ductal carcinoma, modified radical mastectomy with axillary lymph node dissection was performed. Surprisingly, related pathology report referred only to the mesenchymal component. The optimal treatment of MBC is not well-known yet, and the current approach is paralleled with other IDC subtypes. Therefore, studies about the MBC biologic markers can demonstrate new treatment approaches. This issue can be a milestone in the management of MBC, which targeting mesenchymal component in systemic therapy can improve clinical consequences.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.